The Arizona Department of Health Services yesterday recommended resuming the use of the Johnson & Johnson vaccine after the CDC and FDA safety review Sunday.
On Friday, the Advisory Committee on Immunization Practices voted to recommend the J&J vaccine, but members wanted clear messaging about the possible risks for women younger than 50 years old.
On April 13, the CDC and FDA recommended pausing the vaccine after six reported cases of a rare adverse event among women developed blood clotting with low blood platelets after receiving J&J. The CDC determined the event is rare, occurring at a rate of 7 per 1 million vaccinated women between the age of 18 to 49.